DOI QR코드

DOI QR Code

MiR-454 Prompts Cell Proliferation of Human Colorectal Cancer Cells by Repressing CYLD Expression

  • Liang, Hong-Liang ;
  • Hu, Ai-Ping ;
  • Li, Sen-Lin ;
  • Xie, Jia-Ping ;
  • Ma, Qing-Zhu ;
  • Liu, Ji-Yong
  • Published : 2015.04.03

Abstract

Previous studies have shown that miR-454 plays an important role in a variety of biological processes in various human cancer cells. However, the underlying mechanisms of this microRNA in colorectal cancer (CRC) cells remain largely unknown. In the present study, we investigated the miR-454 role in CRC cell proliferation. We found that miR-454 expression is markedly upregulated in CRC tissues and CRC cells compared with the matched tumor adjacent tissues and the FHC normal colonic cell line. Ectopic expression of miR-454 promoted the proliferation and anchorage-independent growth of CRC cells, whereas inhibition of miR-454 reduced this effect. Bioinformatics analysis further revealed cylindromatosis (CYLD), a putative tumor suppressor as a potential target of miR-454. Data from luciferase reporter assays showed that miR-454 directly binds to the 3'-untranslated region (3'-UTR) of CYLD mRNA and repressed expression at both transcriptional and translational levels. In functional assays, CYLD-silenced in miR-454-in-transfected SW480 cells have positive effect to promote cell proliferation, suggesting that direct CYLD downregulation is required for miR-454-induced CRC cell proliferation. In sum, our data provide compelling evidence that miR-454 functions as an onco-miRNA, playing a crucial role in the promoting cell proliferation in CRC, and its oncogenic effect is mediated chiefly through direct suppression of CYLD expression.

Keywords

miR-454;colorectal cancer;CYLD;cell proliferation

References

  1. Alameda JP, Moreno-Maldonado R, Navarro M, et al (2010). An inactivating CYLD mutation promotes skin tumor progression by conferring enhanced proliferative, survival and angiogenic properties to epidermal cancer cells. Oncogene, 29, 6522-32. https://doi.org/10.1038/onc.2010.378
  2. Ambros V (2004). The functions of animal microRNAs. Nature, 431, 350-5. https://doi.org/10.1038/nature02871
  3. Andre T, Tuvignon N, Taieb J, et al (2010). Operable colon cancer: initial strategy. Rev Prat, 60, 1089-93.
  4. Aschele C, Bergamo F, Lonardi S (2009). Chemotherapy for operable and advanced colorectal cancer. Cancer Treat Rev, 35, 509-16. https://doi.org/10.1016/j.ctrv.2009.04.003
  5. Bartel DP (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 116, 281-97. https://doi.org/10.1016/S0092-8674(04)00045-5
  6. Calin GA, Croce CM (2006). MicroRNA signatures in human cancers. Nat Rev Cancer, 6, 857-66. https://doi.org/10.1038/nrc1997
  7. Chen P, Wang BL, Pan BS, et al (2014). MiR-1297 regulates the growth, migration and invasion of colorectal cancer cells by targeting cyclo-oxygenase-2. Asian Pac J Cancer Prev, 15, 9185-90. https://doi.org/10.7314/APJCP.2014.15.21.9185
  8. Esquela-Kerscher A, Slack FJ (2006). Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer, 6, 259-69. https://doi.org/10.1038/nrc1840
  9. Gao Y, Li BD, Liu YG (2013). Effect of miR27a on proliferation and invasion in colonic cancer cells. Asian Pac J Cancer Prev, 14, 4675-8. https://doi.org/10.7314/APJCP.2013.14.8.4675
  10. Iliopoulos D, Jaeger SA, Hirsch HA, et al (2010). STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol Cell, 39, 493-506. https://doi.org/10.1016/j.molcel.2010.07.023
  11. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
  12. Kinoshita H, Okabe H, Beppu T, et al (2013). CYLD downregulation is correlated with tumor development in patients with hepatocellular carcinoma. Mol Clin Oncol, 1, 309-14.
  13. Knudsen KE, Diehl JA, Haiman CA, et al (2006). Cyclin D1: polymorphism, aberrant splicing and cancer risk. Oncogene, 25, 1620-8. https://doi.org/10.1038/sj.onc.1209371
  14. Massoumi R, Chmielarska K, Hennecke K, et al (2006). Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-kappaB signaling. Cell, 125, 665-77. https://doi.org/10.1016/j.cell.2006.03.041
  15. Miliani de Marval P, Lutfeali S, Jin JY, et al (2011). CYLD inhibits tumorigenesis and metastasis by blocking JNK/AP1 signaling at multiple levels. Cancer Prev Res, 4, 851-9. https://doi.org/10.1158/1940-6207.CAPR-10-0360
  16. Primrose JN (2010). Surgery for colorectal liver metastases. Br J Cancer, 102, 1313-8. https://doi.org/10.1038/sj.bjc.6605659
  17. Raman M, Ambalam P, Kondepudi KK, et al (2013). Potential of probiotics, prebiotics and synbiotics for management of colorectal cancer. Gut Microbes, 4, 181-92. https://doi.org/10.4161/gmic.23919
  18. Ratschiller D, Heighway J, Gugger M, et al (2003). Cyclin D1 overexpression in bronchial epithelia of patients with lung cancer is associated with smoking and predicts survival. J Clin Oncol, 21, 2085-93. https://doi.org/10.1200/JCO.2003.03.103
  19. Rico-Rosillo MG, Vega-Robledo GB, Oliva-Rico D (2014). The role and importance of the microRNAs in the diagnosis and development of diseases. Rev Med Inst Mex Seguro Soc, 52, 302-7.
  20. Roy AL, Carruthers C, Gutjahr T, et al (1993). Direct role for Myc in transcription initiation mediated by interactions with TFII-I. Nature, 365, 359-61. https://doi.org/10.1038/365359a0
  21. Sharma M, Sharma S, Arora M, et al (2013). Regulation of cellular Cyclin D1 gene by arsenic is mediated through miR-2909. Gene, 522, 60-4. https://doi.org/10.1016/j.gene.2013.03.058
  22. Shi L, Wang Z, Sun G, et al (2014). miR-145 inhibits migration and invasion of glioma stem cells by targeting ABCG2. Neuromolecular Med, 16, 517-28. https://doi.org/10.1007/s12017-014-8305-y
  23. Suppiah A, Hartley JE, Monson JR (2009). Advances in radiotherapy in operable rectal cancer. Dig Surg, 26, 187-99. https://doi.org/10.1159/000219931
  24. Xia JT, Chen LZ, Jian WH, et al (2014). MicroRNA-362 induces cell proliferation and apoptosis resistance in gastric cancer by activation of NF-kappaB signaling. J Transl Med, 12, 33. https://doi.org/10.1186/1479-5876-12-33
  25. Zhang L, Dong Y, Zhu N, et al (2014). microRNA-139-5p exerts tumor suppressor function by targeting NOTCH1 in colorectal cancer. Mol Cancer, 13, 124. https://doi.org/10.1186/1476-4598-13-124
  26. Zhong Q, Wang T, Lu P, et al (2014). miR-193b promotes cell proliferation by targeting Smad3 in human glioma. J Neurosci Res, 92, 619-26. https://doi.org/10.1002/jnr.23339

Cited by

  1. Comparison of the miRNA profiles in HPV-positive and HPV-negative tonsillar tumors and a model system of human keratinocyte clones vol.16, pp.1, 2016, https://doi.org/10.1186/s12885-016-2430-y
  2. MiR-130b inhibits proliferation and induces apoptosis of gastric cancer cells via CYLD vol.37, pp.6, 2016, https://doi.org/10.1007/s13277-015-4632-3
  3. MicroRNA-454 may function as an oncogene via targeting AKT in triple negative breast cancer vol.24, pp.1, 2017, https://doi.org/10.1186/s40709-017-0067-x
  4. miR-922 regulates CYLD expression and promotes the cell proliferation of human hepatocellular carcinoma vol.37, pp.3, 2017, https://doi.org/10.3892/or.2017.5431
  5. miR-130b regulates the proliferation, invasion and apoptosis of glioma cells via targeting of CYLD vol.38, pp.1, 2017, https://doi.org/10.3892/or.2017.5651
  6. MicroRNAs in the prognosis of triple-negative breast cancer vol.96, pp.22, 2017, https://doi.org/10.1097/MD.0000000000007085
  7. MicroRNA-454 inhibits tumor cell proliferation, migration and invasion by downregulating zinc finger E-box-binding homeobox 1 in gastric cancer vol.16, pp.6, 2017, https://doi.org/10.3892/mmr.2017.7758

Acknowledgement

Supported by : Shandong Provincial Hospital